Pharmaceutics (Dec 2022)

Exploring Freeze-Drying as Strategy to Enhance Viability of <i>Faecalibacterium duncaniae</i> DSM 17677 upon Aerobic Storage and Gastrointestinal Conditions

  • Daniela Machado,
  • Melany Domingos,
  • Joana Cristina Barbosa,
  • Diana Almeida,
  • José Carlos Andrade,
  • Ana Cristina Freitas,
  • Ana Maria Gomes

DOI
https://doi.org/10.3390/pharmaceutics14122735
Journal volume & issue
Vol. 14, no. 12
p. 2735

Abstract

Read online

Faecalibacterium duncaniae is an intestinal commensal bacterium proposed as a next-generation probiotic due to its promising outcomes in the treatment and prevention of several human diseases, which demonstrate its multiple contributions to the host’s health. However, its strict anaerobic nature has created several hurdles in the development of functional foods, nutraceuticals, and biotherapeutic products. Herein, we explored freeze-dried formulations containing prebiotics, cryoprotectants, and antioxidant agents as a technological strategy to enhance the viability of F. duncaniae DSM 17677 upon aerobic storage and gastrointestinal tract conditions. Our results indicate that freeze-dried F. duncaniae in a matrix containing inulin, sucrose, cysteine, and riboflavin survived at levels higher than 106 CFU/g and around 105 CFU/g after 1 and 4 days of aerobic storage at room temperature, respectively. Thus, the freeze-dried formulation with inulin, sucrose, cysteine, and riboflavin presents as a protective strategy to improve F. duncaniae viability under aerobic environments. Nevertheless, incorporation of a suitable coating aimed at protecting F. duncaniae against the detrimental gastrointestinal passage effects is urgently required, given its high susceptibility to extreme acidic pH values and bile.

Keywords